Many human malignancies are associated with aberrant regulation of protein or lipid
kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein …

In 2014, the Immunosuppressive Drugs Scientific Committee of the International Association
of Therapeutic Drug Monitoring and Clinical Toxicology called a meeting of international …

Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the
efficacy and safety outcomes of this treatment after kidney transplant require confirmation …

TRANSFORM (TRANSplant eFficacy and safety Outcomes with an eveRolimus-based
regiMen) was a 24-month, prospective, open-label trial in 2037 de novo renal transplant …

This study compared the incidence of CMV infection/disease in de novo kidney transplant
recipients receiving everolimus or mycophenolate and no CMV pharmacological …

Results We included 28 randomized, controlled trials with 6211 participants classified into
comparison 1: mTOR inhibitor versus calcineurin inhibitor and comparison 2: mTOR inhibitor …

ZEUS study was an open-label, 12-month, multicenter study in which 300 de novo kidney
transplant recipients were randomized to continue receiving cyclosporine (CsA) or convert to …

Despite their clinical efficacy, concerns about calcineurin inhibitor (CNI) toxicity make
alternative regimens that reduce CNI exposure attractive for renal transplant recipients. In …

Tacrolimus was discovered in 1984 and entered clinical use shortly thereafter, contributing
to successful solid organ transplantation across the globe. In this review, we cover …

As the risk of graft loss due to acute rejection has declined, the goal of post-transplant
management has switched to long-term preservation of organ function. Minimizing …